<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Central Admin - Research Services</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0E5A920B-938D-459F-A7C4-21C1F2E876FF"><gtr:id>0E5A920B-938D-459F-A7C4-21C1F2E876FF</gtr:id><gtr:firstName>Marion</gtr:firstName><gtr:otherNames>Hanbury</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EFD541EC-F53F-4F79-BFA5-8DCE70466421"><gtr:id>EFD541EC-F53F-4F79-BFA5-8DCE70466421</gtr:id><gtr:firstName>A</gtr:firstName><gtr:otherNames>Neil</gtr:otherNames><gtr:surname>Barclay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601169"><gtr:id>18ACE0F4-3121-4855-8145-60DF4C342038</gtr:id><gtr:title>The molecular basis for the specificity and signalling through the CD200 paired receptor family</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601169</gtr:grantReference><gtr:abstractText>The immune system is remarkable in that it can recognise foreign materials such as bacteria and viruses without having encountered them before and make a measured response that leads to their elimination. It can distinguish between small infections at the site of for example a bite, from a viral infection like influenza that calls for all the power of the immune system to be mobilised. This control is effected by white blood cells patrolling the body waiting to react. As mentioned the nature of the responses is highly controlled and this is mediated by interactions of proteins at the surface of the blood cells with other cells. 
This proposal looks at one class of proteins called ?paired receptors? that have been implicated in virus defence and have the intriguing property that they can give very different signals although the bit that recognises other cells is quite similar. The study focuses on a protein called CD200R that is currently being evaluated as a possible therapeutic target. The aim is to understand the mechanisms involved at a molecular level for this interaction where the detailed information may be applicable to this class of proteins. The importance of understanding the subtleties of these types of interactions was made abundantly obvious in the recent clinical trials of a leukocyte therapeutic target CD28. Here it appears that differences in interactions between two closely related species were sufficient to cause a dramatic life threatening and unexpected response. 
The type of quantitative molecular analysis in this study will identify parameters involved in determining the signal produced with relevance for therapies involving this type of target and for the general understanding of the immune system. Thus it will have implications in understanding and treating diseases like cancer, infectious diseases and autoimmune disease such as arthritis, diabetes.</gtr:abstractText><gtr:technicalSummary>Paired receptors contain one gene giving an inhibitory membrane receptor and several other genes (according to species) giving a completely opposite activating signal despite close sequence similarity of the ligand binding region. Several families have been characterised and shown to be involved in fine tuning of a variety of immune responses. We will study the mechanisms involved using a paired receptor - the CD200R system. CD200 binds the inhibitory CD200R but shows negligible binding to the activating receptors. What the activating receptors bind is a major question for many of these proteins. Given the possible strong amplification of signals through dimerisation of activating receptors and their association with DAP12, this binding may be significant and this project investigates this by using new more sensitive methods to detect weak interactions coupled with functional analysis involving cell contact of cells with these receptors and cells expressing different levels of ligand. We will determine;
1. Do all the mouse CD200RL?s bind CD200 and can these proteins give activating signals on CD200 engagement?
2. Is human CD200RLa expressed on normal cells and does it bind CD200 and give activating signals on CD200 engagement? 
3. Are levels of ligand and receptor expression critical for balance of activating and inhibiting signals through the CD200Rs?
4. What is the structural basis for the difference in affinity given the sequence similarity between the various CD200R gene products?
5. Are the activating receptors dimeric and can their activity be modulated by reduction of cystine bridges?
The results will have general implications for immunoregulation through this type of receptor family and also be important in current exploitation efforts that are focussed on targeting myeloid cells in inflammation (collaboration with Schering-Plough).</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-07-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>342731</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Monoclonal antibody</gtr:description><gtr:id>CEC8169B-2138-4F38-8463-BC31F7082739</gtr:id><gtr:impact>gives new insight into family of receptors</gtr:impact><gtr:outcomeId>2B3F2E8284A</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Monoclonal antibody</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DD08F927-E465-406E-BAFA-E878BE0F9E24</gtr:id><gtr:title>Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f48cee2e46348c1d2864bad83c9ac2"><gtr:id>c4f48cee2e46348c1d2864bad83c9ac2</gtr:id><gtr:otherNames>Mihrshahi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>3594121B_93594121B_9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71942B37-D6D5-4E04-9981-B32A21EE3B30</gtr:id><gtr:title>Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f48cee2e46348c1d2864bad83c9ac2"><gtr:id>c4f48cee2e46348c1d2864bad83c9ac2</gtr:id><gtr:otherNames>Mihrshahi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>21B06744BB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBA0C4A0-48D8-4980-A789-A1427703F543</gtr:id><gtr:title>Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200).</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/917fedf7d4ac4a5d4fbb9db6070723d7"><gtr:id>917fedf7d4ac4a5d4fbb9db6070723d7</gtr:id><gtr:otherNames>Zhang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>C2C3F0F8108</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4717B36-33C9-45C4-AC37-0A0DBC986A2A</gtr:id><gtr:title>Heterogeneity in the CD200R paired receptor family.</gtr:title><gtr:parentPublicationTitle>Immunogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/254f024c16d865180d3aedd11b23fa3e"><gtr:id>254f024c16d865180d3aedd11b23fa3e</gtr:id><gtr:otherNames>Akkaya M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0093-7711</gtr:issn><gtr:outcomeId>pBUKeTwLop4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601169</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>